Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Jiansheng ^a,b   Zhao, Peng ^a,b   Li, Ya ^a,b   Tian, Yange ^a,b   Wang, Yonghua ^b,c  

^a HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^b Key Laboratory of Chinese Internal Medicine   (China)

^c NORTHWEST A F UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BU-FEI-YI-SHEN; COLLAGEN; CYTOKINE; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT;

ANIMAL; CARDIAC MUSCLE; CHINESE MEDICINE; DRUG EFFECTS; GENETICS; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG; METABOLISM; PATHOLOGY; PHYTOTHERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; COLLAGEN; CYTOKINES; DRUGS, CHINESE HERBAL; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEDICINE, CHINESE TRADITIONAL; MYOCARDIUM; PHYTOTHERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84944315642     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15290     Document Type: Article

References (42)

1. Vanfleteren, L. E. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 187, 728-735 (2013).
2. Eisner, M. D. et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 182, 693-718 (2010).
3. Wedzicha, J. A. & Seemungal, T. A. COPD exacerbations: defining their cause and prevention. Lancet 370, 786-796 (2007).
4. Vestbo, J. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care. Med. 187, 347-365 (2013).
5. Li, S. Y. et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern. Med. 12, 197 (2012).
6. Normile, D. Asian medicine. The new face of traditional Chinese medicine. Science (New York, NY) 299, 188-190 (2003).
7. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
8. Janga, S. C. & Tzakos, A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol. Biosyst. 5, 1536-1548 (2009).
9. Hao da, C. & Xiao, P. G. Network pharmacology: a Rosetta Stone for traditional Chinese medicine. Drug. Dev. Res. 75, 299-312 (2014).
10. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002).
11. Ma, C., Wang, L. & Xie, X. Q. GPU accelerated chemical similarity calculation for compound library comparison. J. Chem. Inf. Model. 51, 1521-1527 (2011).
12. Morwood, C. J. & Lappas, M. The citrus flavone nobiletin reduces pro-inflammatory and pro-labour mediators in fetal membranes and myometrium: implications for preterm birth. PloS one 9, e108390 (2014).
13. Park, J. S. et al. Statistically designed enzymatic hydrolysis for optimized production of icariside II as a novel melanogenesis inhibitor. J. Microbiol. Biotechnol. 18, 110-117 (2008).
14. Lin, Y., Shi, R., Wang, X. & Shen, H. M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets 8, 634-646 (2008).
15. Chen, C., Zhou, J. & Ji, C. Quercetin: a potential drug to reverse multidrug resistance. Life sci. 87, 333-338 (2010).
16. Devi, K. P. et al. Kaempferol and inflammation: From chemistry to medicine. Pharmacol. Res. 99, 1-10 (2015).
17. Suleyman, H., Demircan, B. & Karagoz, Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep.: PR 59, 247-258 (2007).
18. Ndisang, J. F. Cross-talk between heme oxygenase and peroxisome proliferator-activated receptors in the regulation of physiological functions. Front. Biosci. (Landmark Ed.) 19, 916-935 (2014).
19. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091-1093 (2009).
20. Tse, H. N. & Tseng, C. Z. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 825-836 (2014).
21. Banerjee, A., Koziol-White, C. & Panettieri, R., Jr. p38 MAPK inhibitors, IKK2 inhibitors, and TNFalpha inhibitors in COPD. Curr. Opin. Pharmacol. 12, 287-292 (2012).
22. Rodriguez, M. et al. Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals. Mol. Pharmacol. 85, 187-197 (2014).
23. Calderon-Garciduenas, L. et al. Pediatric respiratory and systemic effects of chronic air pollution exposure: nose, lung, heart, and brain pathology. Toxicol. Pathol. 35, 154-162 (2007).
24. Barnes, P. J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 35, 71-86 (2014).
25. Chung, K. F. Cytokines as targets in chronic obstructive pulmonary disease. Curr. drug targets 7, 675-681 (2006).
26. Muroski, M. E. et al. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9, 34-46 (2008).
27. Atkinson, J. J. & Senior, R. M. Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 28, 12-24 (2003).
28. Demkow, U. & van Overveld, F. J. Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment. Eur. J. Med. Res. 15 Suppl 2, 27-35 (2010).
29. Leeming, D. J. et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark. insights 7, 119-126 (2012).
30. Nemeth, K. et al. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr. 42, 29-42 (2003).
31. Xu, X. et al. A novel chemometric method for the prediction of human oral bioavailability. Int. J. Mol. Sci. 13, 6964-6982 (2012).
32. van der Graaf, P. H. & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. res. 28, 1460-1464 (2011).
33. Manna, K. et al. Naringin inhibits gamma radiation-induced oxidative DNA damage and inflammation, by modulating p53 and NF-kappaB signaling pathways in murine splenocytes. Free radic. res. 49, 422-439 (2015).
34. Ciftci, O. et al. Hesperidin, a Citrus Flavonoid, Has the Ameliorative Effects Against Experimental Autoimmune Encephalomyelitis (EAE) in a C57BL/J6 Mouse Model. Neurochem. res (2015).
35. Bajracharya, G. B. Diversity, pharmacology and synthesis of bergenin and its derivatives: potential materials for therapeutic usages. Fitoterapia 101, 133-152 (2015).
36. Lakshmi, A. & Subramanian, S. P. Tangeretin ameliorates oxidative stress in the renal tissues of rats with experimental breast cancer induced by 7,12-dimethylbenz[a]anthracene. Toxicol. lett. 229, 333-348 (2014).
37. Zhang, J. et al. Paeoniflorin selectively inhibits LPS-provoked B-cell function. J. Pharmacol. Sci. 128, 8-16 (2015).
38. Ryu, G. et al. A new antioxidant monoterpene glycoside, alpha-benzoyloxypaeoniflorin from Paeonia suffruticosa. Arch. Pharm. Res. 24, 105-108 (2001).
39. Yu, H. et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PloS one 7, e37608 (2012).
40. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).
41. Li, Y. et al. A rat model for stable chronic obstructive pulmonary disease induced by cigarette smoke inhalation and repetitive bacterial infection. Biol. Pharm. Bull. 35, 1752-1760 (2012).
42. Hnizdo, E. Lung function loss associated with occupational dust exposure in metal smelting. Am. J. Respir. Crit. Care. Med. 181, 1162-1163 (2010).